Abstract
Extreme concern about opioid overdoses and overdose deaths among young people is dovetailing with solutions — in particular, expanding treatment with buprenorphine and methadone for this population. Expansion of treatment for adolescents and young adults — ages 15 to 25 — with opioid use disorders (OUDs) is critical, researcher after researcher has written. But there has been a reticence by parents in particular, and even by some clinicians, about prescribing buprenorphine, a Schedule III opioid, to young people, or to sending them to an opioid treatment program (the only kind of facility in the United States where methadone can be dispensed for OUD). Both medications can be given to youth as young as 16.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
